Suppression of the IgE-dependent allergic response by benzimidazole analogs
AssigneeAvanir Pharmaceuticals
InventorsJagadish C. Sircar, Mark L. Richards, Michael G. Campbell, Michael W. Major
Life of this patent
Estimating the term…
Abstract
The present invention is directed to small molecule inhibitors of the IgE response to allergens which are useful in the treatment of allergy and/or asthma or any diseases where IgE is pathogenic.
Claims15
A compound for use in treating or preventing an allergic reaction which is caused by an increase in plasma IgE levels, the compound having a formula:
- wherein X and Y are independently selected from the group consisting of H, halogen, alkyl, alkoxy, aryl, substituted aryl, hydroxy, amino, alkylamino, cycloalkyl, morpholine, thiomorpholine, nitro, cyano, CF3 and OCF3;
- wherein R is selected from the group consisting of H, CH3, C2H5, C3H7 and C4H9;
- and
- where R1 and R2 are independently selected from the group consisting of H, alkyl, cycloalkyl, substituted cycloalkyl, polycycloalkyl, substituted polycycloalkyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl, and wherein R1 and R2 are not phenyl groups.
A method for treating or preventing an allergic reaction which is caused by an increase in plasma IgE levels in a mammal which comprises administering to said mammal an IgE-suppressing amount of a pharmaceutical formulation comprising a compound having a formula:
- wherein X and Y are independently selected from the group consisting of H, halogen, alkyl, alkoxy, aryl, substituted aryl, hydroxy, amino, alkylamino, cycloalkyl, morpholine, thiomorpholine, nitro, cyano, CF3 and OCF3;
- wherein R is selected from the group consisting of H, CH3, C2H5, C3H7 and C4H9;
- and
- where R1 and R2 are independently selected from the group consisting of H, alkyl, cycloalkyl, substituted cycloalkyl, polycycloalkyl, substituted polycycloalkyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl.
A method for treating or preventing asthma which is caused by an increase in plasma IgE levels in a mammal which comprises administering to said mammal an IgE-suppressing amount of a pharmaceutical formulation comprising a compound having a formula:
- wherein X and Y are independently selected from the group consisting of H, halogen, alkyl, alkoxy, aryl, substituted aryl, hydroxy, amino, alkylamino, cycloalkyl, morpholine, thiomorpholine, nitro, cyano, CF3 and OCF3;
- wherein R is selected from the group consisting of H, CH3, C2H5, C3H7 and C4H9;
- and where R1 and R2 are independently selected from the group consisting of H, alkyl, cycloalkyl, substituted cycloalkyl, polycycloalkyl, substituted polycycloalkyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl.
Dependencies are inferred from the claim text.